Lantus is the best-selling diabetes drug in the world right now and the top-selling drug for Sanofi. But the drug goes off patent in 2015, so the French drugmaker is coming on strong with its Lantus successor, known as U300.
Hospira and its biosimilar partner Celltrion won European approval for the first biosimilar of a monoclonal antibody therapy in September when t he EU signed off on their Inflectra, a biosimilar of Johnson & Johnson's Remicade. But despite the achievement, the partners still face a huge challenge: getting doctors to use the drug.
The world's largest drug developers are getting less and less from their R&D spends, according to a report, struggling to deal with ever-escalating development costs as returns diminish.
Despite a major setback earlier this year when the FDA rejected Novo Nordisk's application for Tresiba, forcing a new cardio study, the Danish pharma company's CEO is boasting that the company has a strong R&D effort underway.
Seattle-based Blaze Bioscience has rounded up $9 million in venture cash from a wide circle of angel investors willing to back the biotech's push into the clinic with its first "tumor paint" product.
Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world.
The new CEO at Forest Laboratories is committing to what has become a common ritual in the industry, gearing up for a major reorganization with a special focus on slashing research costs.
Global R&D spending is unlikely to grow by much more than single digits over the next 5 years, but that won't do much harm to the world's biggest CROs, according to a Morningstar analyst, as the industry's heavyweights are only digging deeper into the operations of their sponsors.
Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.
Theraclone Sciences was hoping for a federal cash infusion to keep its anti-influenza antibody program rolling, but a denial from the government will force the biotech to handle Phase II on its own.